Jiao Lyu1, Qi Zhang1, Haiying Jin1, Yu Xu1, Chunli Chen2, Xunda Ji1, Xiang Zhang1, Yuqing Rao1, Peiquan Zhao3. 1. Department of Ophthalmology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, 1665 Kong Jiang Road, Shanghai, 200092, China. 2. Department of Ophthalmology, Shengli Oilfield Central Hospital, Dongying, Shan Dong Province, China. 3. Department of Ophthalmology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, 1665 Kong Jiang Road, Shanghai, 200092, China. zhaopeiquanxh@163.com.
Abstract
PURPOSE: To determine the aqueous humor levels of cytokines in eyes with type 1 retinopathy of prematurity (ROP) before primary intravitreal injection of ranibizumab (IVR). METHODS: Forty-nine infants with type 1 ROP (56 eyes of 28 infants in the threshold ROP group and 42 eyes of 21 infants in the type 1 pre-threshold ROP group) received primary IVR and 49 aqueous humor samples were obtained preoperatively. Aqueous humor samples from 15 infants (15 eyes) undergoing congenital cataract surgery were used as controls. The concentrations of 27 cytokines were measured by a multiplex bead assay. Infants with persistent, recurrent, or progressive ROP after IVR were retreated. RESULTS: The preoperative aqueous levels of 16 cytokines were significantly different among type 1 pre-threshold, threshold ROP, and control groups (P < 0.05). The concentrations of vascular endothelial growth factor (VEGF) (P < 0.001), interferon-γ (P < 0.001), interleukin (IL)-10 (P < 0.001), and IL-12 (P < 0.001) were the highest in the threshold ROP group, less in the type 1 pre-threshold ROP group, and the lowest in the control group. Retreatment was given to 55% of infants with ROP within a 48-week follow-up period after primary IVR. Higher VEGF (hazard ratio [HR] = 1.001, P = 0.001) and macrophage inflammatory protein-1β (HR = 1.085, P = 0.022) levels were independently correlated with ROP retreatment. CONCLUSIONS: Higher aqueous levels of VEGF and inflammatory cytokines were associated with more severe type 1 ROP and ROP retreatment after primary IVR.
PURPOSE: To determine the aqueous humor levels of cytokines in eyes with type 1 retinopathy of prematurity (ROP) before primary intravitreal injection of ranibizumab (IVR). METHODS: Forty-nine infants with type 1 ROP (56 eyes of 28 infants in the threshold ROP group and 42 eyes of 21 infants in the type 1 pre-threshold ROP group) received primary IVR and 49 aqueous humor samples were obtained preoperatively. Aqueous humor samples from 15 infants (15 eyes) undergoing congenital cataract surgery were used as controls. The concentrations of 27 cytokines were measured by a multiplex bead assay. Infants with persistent, recurrent, or progressive ROP after IVR were retreated. RESULTS: The preoperative aqueous levels of 16 cytokines were significantly different among type 1 pre-threshold, threshold ROP, and control groups (P < 0.05). The concentrations of vascular endothelial growth factor (VEGF) (P < 0.001), interferon-γ (P < 0.001), interleukin (IL)-10 (P < 0.001), and IL-12 (P < 0.001) were the highest in the threshold ROP group, less in the type 1 pre-threshold ROP group, and the lowest in the control group. Retreatment was given to 55% of infants with ROP within a 48-week follow-up period after primary IVR. Higher VEGF (hazard ratio [HR] = 1.001, P = 0.001) and macrophage inflammatory protein-1β (HR = 1.085, P = 0.022) levels were independently correlated with ROP retreatment. CONCLUSIONS: Higher aqueous levels of VEGF and inflammatory cytokines were associated with more severe type 1 ROP and ROP retreatment after primary IVR.
Entities:
Keywords:
Aqueous humor; Cytokine; Ranibizumab; Retinopathy of prematurity
Authors: Raul Velez-Montoya; Carmen Clapp; Jose Carlos Rivera; Gerardo Garcia-Aguirre; Virgilio Morales-Cantón; Jans Fromow-Guerra; Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado Journal: Clin Ophthalmol Date: 2010-09-07
Authors: David K Wallace; Raymond T Kraker; Sharon F Freedman; Eric R Crouch; Amy K Hutchinson; Amit R Bhatt; David L Rogers; Michael B Yang; Kathryn M Haider; Deborah K VanderVeen; R Michael Siatkowski; Trevano W Dean; Roy W Beck; Michael X Repka; Lois E Smith; William V Good; Mary Elizabeth Hartnett; Lingkun Kong; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2017-06-01 Impact factor: 7.389
Authors: Jie Ma; Manisha Mehta; Godfrey Lam; Desireé Cyr; Tat Fong Ng; Tatsuo Hirose; Khaled A Tawansy; Andrew W Taylor; Kameran Lashkari Journal: Mol Vis Date: 2014-06-21 Impact factor: 2.367